Moderna (MRNA) Depreciation & Amortization (CF) (2018 - 2026)

Moderna (MRNA) has 9 years of Depreciation & Amortization (CF) data on file, last reported at $59.0 million in Q1 2026.

• Depreciation & Amortization (CF) for Q1 2026 came in at $59.0 million, up 51.28% year-over-year; the trailing twelve-month figure through Mar 2026 was $235.0 million (up 22.4% YoY), and the FY2025 annual result was $215.0 million, up 13.76% from the prior year.
• Depreciation & Amortization (CF) slipped to $59.0 million in Q1 2026 per MRNA's latest filing, from $67.0 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $249.0 million in Q3 2023 and troughed at $36.0 million in Q1 2024.
• A 5-year average of $84.2 million and a median of $67.0 million in 2025 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2024: Depreciation & Amortization (CF) surged 426.67% in 2022, then sank 79.12% in 2024.
• A 5-year view of Depreciation & Amortization (CF) shows it stood at $80.0 million in 2022, then surged by 152.5% to $202.0 million in 2023, then plunged by 70.3% to $60.0 million in 2024, then rose by 11.67% to $67.0 million in 2025, then fell by 11.94% to $59.0 million in 2026.
• Business Quant data shows MRNA's Depreciation & Amortization (CF) at $59.0 million in Q1 2026, $67.0 million in Q4 2025, and $52.0 million in Q3 2025.